docetaxel anhydrous has been researched along with Carcinoma, Intraepithelial in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gellhaus, PT; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Steinberg, RL | 1 |
| Gellhaus, PT; Martin, AC; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Richards, J; Steinberg, RL | 1 |
| Atallah, W; Gupta, M; Katims, AB; Mehrazin, R; Rosen, DC; Tam, AW; Zampini, AM | 1 |
| Amarillo, I; Fisher, SI; Rashidi, A | 1 |
| Hayashida, T; Ikeda, T; Jinno, H; Kitagawa, Y; Mukai, M; Sakata, M; Takahashi, M | 1 |
| Furukawa, T; Irie, K; Iwanaga, K; Katoh, O; Kuroki, S | 1 |
1 trial(s) available for docetaxel anhydrous and Carcinoma, Intraepithelial
| Article | Year |
|---|---|
A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma in Situ; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Period; Taxoids; Treatment Outcome | 2010 |
5 other study(ies) available for docetaxel anhydrous and Carcinoma, Intraepithelial
| Article | Year |
|---|---|
Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Docetaxel; Doxorubicin; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Urinary Bladder Neoplasms | 2022 |
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Carcinoma in Situ; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Novel treatment of upper tract urothelial carcinoma in situ with docetaxel in BCG refractory patients.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Cohort Studies; Docetaxel; Humans; Kidney Neoplasms; Middle Aged; Treatment Failure; Ureteral Neoplasms | 2021 |
BRCA2-associated therapy-related acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Genes, BRCA2; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Taxoids | 2015 |
[A case of synchronous bilateral double primary lung cancer successfully treated by Nd-YAG laser therapy and chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Humans; Laser Therapy; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Taxoids | 1999 |